Abstract Background: Pneumosepsis is a severe and potentially life-threatening infection of the lower respiratory tract. This study aimed to investigate the effect of combined vitamin D and A supplementation on clinical outcomes in patients with pneumosepsis. Material and Methods: Eighty-four patients with pneumosepsis were randomly assigned to four groups in this double-blind clinical trial. Group 1 received standard treatment plus 300,000 IU intramuscular vitamin D and 50,000 IU intramuscular vitamin A. Group 2 received standard treatment plus 300,000 IU intramuscular vitamin D. Group 3 received standard treatment plus 50,000 IU intramuscular vitamin A. Group 4 received standard treatment only. Clinical parameters including ESR, CRP, creatinine, urea, and uric acid levels were recorded at baseline, 24, 48, and 72 hours after intervention. Results: The combined vitamin D and A group (Group 1) demonstrated significantly lower blood pressure, respiratory rate, heart rate, temperature, ESR, CRP, and white blood cell count compared to the other groups at all three time points. Conclusion: The study suggests that combined vitamin D and A supplementation, in addition to standard treatment, may improve clinical outcomes and potentially reduce the duration of hospitalization in patients with pneumosepsis. However, further research is warranted to confirm these findings and elucidate the underlying mechanisms. Trial Registration: This study is registered on Iranian Registry of Clinical Trials (IRCT) under the identifier IRCT20130424013110N10. (The registration date: July 6, 2020).
Jokar et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: